

cket No. JAB-1669
Express Mail Label No. EL 710 606 301 US

Exhibit A-1

SERIAL NO. _____ DOCKET NO. JAB-1669 BY ECC
APPLICATION OF R.Stokbroekx et al. MAILED: 10/19/01
ENTITLED ANGIOGENESIS INHIBITING 5-SUBSTITUTED-1,2,4-THIADIAZOLYL
DERIVATIVES
THE FOLLOWING HAS BEEN RECEIVED IN THE U.S. PATENT OFFICE ON THE DATE STAMPED HEREON:
VIA EXPRESS MAIL NO. EL710839120US

- | | | |
|---|---|---|
| <input type="checkbox"/> AFFIDAVIT | <input checked="" type="checkbox"/> DECLARATION & | <input type="checkbox"/> EXTENSION OF TIME |
| <input checked="" type="checkbox"/> AMENDMENT/PRE. | POA | <input type="checkbox"/> NOTICE OF APPEAL |
| <input type="checkbox"/> ASSIGNMENT FOR RECORDING OATH OR | | <input type="checkbox"/> DECLARATION |
| <input type="checkbox"/> BRIEF | | <input type="checkbox"/> POWER OF ATTORNEY |
| <input checked="" type="checkbox"/> CHARGE TO DEPOSIT ACCOUNT 10-0750 | | <input type="checkbox"/> PRELIMINARY STATEMENT |
| <input type="checkbox"/> DRAWINGS | | <input type="checkbox"/> PRIORITY DOCUMENT |
| <input type="checkbox"/> ISSUE FEE TRANSMITTAL | | <input type="checkbox"/> STATUS INQUIRY |
| <input checked="" type="checkbox"/> LETTER/transmittal | | <input checked="" type="checkbox"/> SPECIFICATION <u>21</u> PGS |
| <input type="checkbox"/> PCT FILING | | <input checked="" type="checkbox"/> CLAIMS <u>17</u> |
| <input checked="" type="checkbox"/> IDS - FORM - 1449 | | <input type="checkbox"/> _____ |

COPY FORWARDED TO ASSIGNEE
DATE: 11/10/03
SIGNED: CEIL SURMAN



**POST OFFICE
TO ADDRESSEE**



EL710839120US

ORIGIN (POSTAL USE ONLY)			DELIVERY (POSTAL USE ONLY)		
PO ZIP Code	Day of Delivery <input type="checkbox"/> Next <input type="checkbox"/> Second	Flat Rate Envelope <input type="checkbox"/>	Delivery Attempt	Time <input type="checkbox"/> AM <input type="checkbox"/> PM	Employee Signature
Date In Mo. Day Year	<input type="checkbox"/> 12 Noon <input type="checkbox"/> 3 PM	Postage \$	Delivery Attempt	Time <input type="checkbox"/> AM <input type="checkbox"/> PM	Employee Signature
Time In <input type="checkbox"/> AM <input type="checkbox"/> PM	Military <input type="checkbox"/> 2nd Day <input type="checkbox"/> 3rd Day	Return Receipt Fee	Delivery Date	Time <input type="checkbox"/> AM <input type="checkbox"/> PM	Employee Signature
Weight lbs. ozs.	Int'l Alpha Country Code	COD Fee Insurance Fee	Signature of Addressee or Agent		
No Delivery <input type="checkbox"/> Weekend <input type="checkbox"/> Holiday	Acceptance Clerk Initials	Total Postage & Fees \$	Name - Please Print		
CUSTOMER USE ONLY METHOD OF PAYMENT: Express Mail Corporate Acct. No. Federal Agency Acct. No. or Postal Service Acct. No.			X X		
FROM: (PLEASE PRINT) ELLEN CIAMBRONE COLETTI, ESQ. JOHNSON & JOHNSON CORP 1 JOHNSON AND JOHNSON PLZ ROOM 3000 WH-3236 NEW BRUNSWICK NJ 08933-0002 JAB-1669			TO: (PLEASE PRINT) ASST. COMMISSIONER OF PATENTS BOX APPLICATION WASHINGTON, D.C. 20231		

PRESS HARD. You are making 3 copies. FOR PICKUP OR TRACKING CALL 1-800-222-1811 www.usps.gov

Mailing Label
Label 11-L July 1997

479,
F02
T

DOCKET NO. JAB-1669

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Raymond A. Stokbroekx; Marc A. Ceusters; Marcel
J.M. Van der Aa; Marcel G.M. Luyckx; Marc Willems
and Robert W. Tuman

For : ANGIOGENESIS INHIBITING 5-SUBSTITUTED-1,2,4-
THIADIAZOLYL DERIVATIVES

Express Mail Certificate

"Express Mail" mailing number: EL710839120US

RECEIVED

Date of Deposit: October 19, 2001


AUG 18 2003

OFFICE OF PETITIONS

I hereby certify that this complete continuation application, including specification pages, claims, Declaration and Power of Attorney, Preliminary Amendment and an Information Disclosure Statement, is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.


Diane Hetzler

(Typed or printed name of person mailing paper or fee)



(Signature of person mailing paper or fee)

Please type a plus sign (+) inside this box ☒

UTILITY PATENT APPLICATION TRANSMITTAL <small>(only for new nonprovisional applications under 37 CFR 1.53(b))</small>		Attorney Docket No. JAB-1669 First Inventor Raymond A. Stokbroekx et al. Title ANGIOGENESIS INHIBITING 5-SUBSTITUTED-1,2,4-THIADIAZOLYL DERIVATIVES Express Mail Label No. EL710839120US
APPLICATION ELEMENTS <small>See MPEP Chapter 600 concerning utility patent application contents.</small>		ADDRESS TO: Commissioner for Patents Box Patent Application Washington, DC 20231
1. <input checked="" type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) <small>(submit an original and a duplicate for fee processing)</small> 2. <input type="checkbox"/> Applicant claims small entity status. 3. <input checked="" type="checkbox"/> Specification [Total Pages 21] <small>(Preferred arrangement set forth below)</small> <ul style="list-style-type: none"> - Descriptive Title of the Invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R&D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure 4. <input type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets] 5. Oath or Declaration [Total Pages 8] a. <input type="checkbox"/> Newly executed (original or copy) b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <small>(for continuation/divisional with Box 18 completed)</small> <ul style="list-style-type: none"> i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). 6. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76		7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) <ul style="list-style-type: none"> a. <input type="checkbox"/> Computer Readable Form (CRF) b. <input type="checkbox"/> Specification Sequence Listing on: <ul style="list-style-type: none"> i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or ii. <input type="checkbox"/> paper c. <input type="checkbox"/> Statement verifying identity of above copies ACCOMPANYING APPLICATION PARTS <ul style="list-style-type: none"> 9. <input type="checkbox"/> Assignment Papers (cover sheet & document(s)) 10. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney <small>(when there is an assignee)</small> 11. <input type="checkbox"/> English Translation Document (if applicable) 12. <input checked="" type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations 13. <input checked="" type="checkbox"/> Preliminary Amendment 14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <small>(Should be specifically itemized)</small> 15. <input type="checkbox"/> Certified Copy of Priority Document(s) <small>(if foreign priority is claimed)</small> 16. <input type="checkbox"/> Request and Certifications under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. 17. <input type="checkbox"/> Other
18. <input checked="" type="checkbox"/> If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: <input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-Part (CIP) of prior application No.: 09/446,591, filed April 21, 2000. Prior application information: Examiner T. Truong Group Art Unit: 1624 For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation <u>can only</u> be relied upon when a portion has been inadvertently omitted from the submitted application parts.		
19. CORRESPONDENCE ADDRESS <input checked="" type="checkbox"/> Customer Number or Bar Code Label 000027777 or <input type="checkbox"/> Correspondence Address below Name: Philip S. Johnson, Esq. Address: Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 USA		
20. TELEPHONE CONTACT Please direct all telephone calls or telefaxes to Ellen Ciambrone Coletti at: Telephone: (732) 524-2359 Fax: (732) 524-2808		
21. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED		
NAME	Steven P. Berman	
SIGNATURE		
DATE	October 19, 2001	